Author

Maria Violeta Mauriz Barreiro

ACCURACY OF FIB-4 AND HEPAMET FIBROSIS SCORE TO IDENTIFY ADVANCED LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
ACCURACY OF FIB-4 AND HEPAMET FIBROSIS SCORE TO IDENTIFY ADVANCED LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Maria Violeta Mauriz Barreiro  et al.

E- CONSULTS IN INFLAMMATORY BOWEL DISEASE (TELEIBD): FACILITATING COMMUNICATION BETWEEN SPECIALIZED AND PRIMARY CARE
E- CONSULTS IN INFLAMMATORY BOWEL DISEASE (TELEIBD): FACILITATING COMMUNICATION BETWEEN SPECIALIZED AND PRIMARY CARE

Maria Violeta Mauriz Barreiro  et al.

DISTINCTIVE CLINICAL FEATURES OF NON-ALCOHOLIC AND MIXED FATTY LIVER DISEASE
DISTINCTIVE CLINICAL FEATURES OF NON-ALCOHOLIC AND MIXED FATTY LIVER DISEASE

Maria Violeta Mauriz Barreiro  et al.

PREVALENCE AND RISK FACTORS ASSOCIATED WITH PROGRESSION TO ADVANCED FIBROSIS AND CIRRHOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): ANALYSIS OF A PROSPECTIVE REGISTRY
PREVALENCE AND RISK FACTORS ASSOCIATED WITH PROGRESSION TO ADVANCED FIBROSIS AND CIRRHOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): ANALYSIS OF A PROSPECTIVE REGISTRY

Maria Violeta Mauriz Barreiro  et al.

OPEN LABEL, RANDOMIZED, CROSSOVER CLINICAL TRIAL TO ASSESS THE EFFICACY OF INCREASING DOSES OF PANCREATIC ENZYMES, WITH OR WITHOUT INHIBITION OF GASTRIC ACID SECRETION, IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY SECONDARY TO CHRONIC PANCREATITIS
OPEN LABEL, RANDOMIZED, CROSSOVER CLINICAL TRIAL TO ASSESS THE EFFICACY OF INCREASING DOSES OF PANCREATIC ENZYMES, WITH OR WITHOUT INHIBITION OF GASTRIC ACID SECRETION, IN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY SECONDARY TO CHRONIC PANCREATITIS

Maria Violeta Mauriz Barreiro  et al.

SURVEILLANCE OF CYSTIC PANCREATIC LESIONS IN PATIENTS OVER 75 YEARS OF AGE
SURVEILLANCE OF CYSTIC PANCREATIC LESIONS IN PATIENTS OVER 75 YEARS OF AGE

Maria Violeta Mauriz Barreiro  et al.

Item 1 - 6 / 6
1